Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020
A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.
EP: 1.Patient Case: A 64-Year-Old Woman With Recurrent Endometrial Cancer
EP: 2.Endometrial Cancer: Factors in Selecting First- and Second-Line Therapy
EP: 3.Immune Checkpoint Inhibitors in Recurrent Endometrial Cancer: Clinical Trial Data
EP: 4.Recurrent Endometrial Cancer: An Evolving Treatment Landscape
EP: 5.Combination IO Strategies in Advanced Endometrial Cancer: RUBY and GY018
EP: 6.Single-Agent IO Therapy in Advanced Endometrial Cancer: PHAEDRA and DOMENICA
EP: 7.Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020
EP: 8.Antibody Drug Conjugate Data in Endometrial Cancer: TROPiCS-03
EP: 9.Future Directions in the Management of Endometrial Cancer
Transcript:
Ritu Salani, MD, MBA: The next trial progress that I want to highlight is the RAINBO MMRd-GREEN trial, which is a phase 3 trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk mismatch repair deficient endometrial cancer. This is an open-label randomized phase 3 trial that's looking at durvalumab once every 4 weeks combined with radiotherapy or radiotherapy alone, for early-stage high-risk patients. Once again, [we are] moving immunotherapy even earlier in the landscape of the treatment. It is going to focus on this mismatch repair deficient endometrial cancers after hysterectomy and staging surgery. Using this molecular classification, we're targeting that high-risk group, so this study will also help inform practice. GY020 is a similar study looking at pembrolizumab in this setting. We're really looking forward to these results to see how this will continue to help inform practice.
Transcript edited for clarity.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More
Ghamande Reviews Latest Chemoimmunotherapy Trials for Endometrial Cancer
March 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sharad A. Ghamande, MD, discussed the significance of the NRG-GY018/KEYNOTE-868 and RUBY trials of immune checkpoint inhibitor plus chemotherapy in patients with advanced endometrial cancer.
Read More
